Mutant Mice Lacking the p53 C-Terminal Domain Model Telomere Syndromes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Mutations in p53, although frequent in human cancers, have not been implicated in telomere-related syndromes. Here, we show that homozygous mutant mice expressing p53Δ31, a p53 lacking the C-terminal domain, exhibit increased p53 activity and suffer from aplastic anemia and pulmonary fibrosis, hallmarks of syndromes caused by short telomeres. Indeed, p53Δ31/Δ31 mice had short telomeres and other phenotypic traits associated with the telomere disease dyskeratosis congenita and its severe variant the Hoyeraal-Hreidarsson syndrome. Heterozygous p53+/Δ31 mice were only mildly affected, but decreased levels of Mdm4, a negative regulator of p53, led to a dramatic aggravation of their symptoms. Importantly, several genes involved in telomere metabolism were downregulated in p53Δ31/Δ31 cells, including Dyskerin, Rtel1, and Tinf2, which are mutated in dyskeratosis congenita, and Terf1, which is implicated in aplastic anemia. Together, these data reveal that a truncating mutation can activate p53 and that p53 plays a major role in the regulation of telomere metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 3×
“To analyze the effect of the targeted mutation, we first excised the LSL cassette ex vivo by adding Cre recombinase to p53 MEFs or to p53 MEFs (Ventura et al., 2007) as controls (Figures 2A and 2B).”
BackgroundMethodInfluentialPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 1×
“, 1990), and mice with equivalent p53 mutations may, like patients with Li-Fraumeni, develop osteosarcomas (Lang et al., 2004; Olive et al., 2004).”
BackgroundRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
Self-citationGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 1×
“, 1990), and mice with equivalent p53 mutations may, like patients with Li-Fraumeni, develop osteosarcomas (Lang et al., 2004; Olive et al., 2004).”
BackgroundArmanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982 · cited 7×
“In murine cells, p53 activation led to the downregulation of four genes including Dyskerin (Dkc1), a gene often mutated in patients with DC (Armanios and Blackburn, 2012).”
BackgroundMethodInfluentialFlow cytometry and FISH to measure the average length of telomeres (flow FISH)
Baerlocher, G. M., Vulto, I., de Jong, G., & Lansdorp, P. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.263 · Cited by 449 · cited 1×
“Telomeric Flow-FISH Flow-FISH was performed as described by Baerlocher et al. (2006). For each animal, the bone marrow from two tibias and two femurs was collected, red blood cells were lysed, then 23 10 cells were fixed in 500 ml PNA hybridization buffer (70% deionized formamide, 20 mM Tris [pH 7.”
MethodBrady, C. A., & Attardi, L. D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064501 · Cited by 403
Regulation of Murine Telomere Length by Rtel
Ding, H., Schertzer, M., Wu, X., Gertsenstein, M., Selig, S., Kammori, M., Pourvali, R., Poon, S., Vulto, I., Chavez, E., et al. (2004) · Cell · doi:10.1016/j.cell.2004.05.026 · Cited by 309 · cited 2×
“Rtel1 appeared as a candidate gene because it is a dominantpositive regulator of telomere length (Ding et al., 2004) that maps 26 cM away from the A/a locus.”
BackgroundDisruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita
Zhong, F., Savage, S. A., Shkreli, M., Giri, N., Jessop, L., Myers, T., Chen, R., Alter, B. P., & Artandi, S. E. (2011) · Genes & Development · doi:10.1101/gad.2006411 · Cited by 262
Feng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 1×
“Furthermore, posttranslational modifications of C-terminal lysines were proposed to be essential for the regulation of p53 stability and activity, but mice with C-terminal lysines mutated into arginines appeared similar to wild-type (WT) mice (Feng et al., 2005; Krummel et al., 2005), except for a hypersensitivity to…”
Backgroundp21/CDKN1A Mediates Negative Regulation of Transcription by p53
Löhr, K., Möritz, C., Contente, A., & Dobbelstein, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212517200 · Cited by 227
Toledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199
Self-citationParry, E. M., Alder, J. K., Qi, X., Chen, J. J.-L., & Armanios, M. (2011) · Blood · doi:10.1182/blood-2010-11-322149 · Cited by 194
Krummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187 · cited 1×
“Furthermore, posttranslational modifications of C-terminal lysines were proposed to be essential for the regulation of p53 stability and activity, but mice with C-terminal lysines mutated into arginines appeared similar to wild-type (WT) mice (Feng et al., 2005; Krummel et al., 2005), except for a hypersensitivity to…”
BackgroundSelf-citationIncreased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389
Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M., Beems, R. B., Miranda, B., van Oostrom, C. T. M., van den Berg, J., van den Aardweg, G. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8884-8894.2004 · Cited by 121
Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development
Terzian, T., Wang, Y., Van Pelt, C. S., Box, N. F., Travis, E. L., & Lozano, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00555-06 · Cited by 116
Wang, Y. V., Leblanc, M., Fox, N., Mao, J.-H., Tinkum, K. L., Krummel, K., Engle, D., Piwnica-Worms, D., Piwnica-Worms, H., Balmain, A., et al. (2011) · Genes & Development · doi:10.1101/gad.2024411 · Cited by 53
Cited by
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Mechanisms of transcriptional regulation by p53
Sullivan, K. D., Galbraith, M. D., Andrysik, Z., & Espinosa, J. M. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.174 · Cited by 446
Telomere-driven diseases and telomere-targeting therapies
Martínez, P., & Blasco, M. A. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610111 · Cited by 257
“Indeed, to our knowledge, the only mouse mutant that faithfully models human HHS does not harbor mutations in any of the known telomere maintenance genes associated with these diseases, but rather a mutation in TP53 gene (Simeonova et al., 2013).”
BackgroundInfluentialChen, J., Crutchley, J., Zhang, D., Owzar, K., & Kastan, M. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0908 · Cited by 93
“15 expressing a p53 protein lacking the carboxyl terminus, similar to the human p53β protein, exhibits deregulated telomere metabolism and premature senescence (45) and overexpression of human p53β induces apoptosis or cellular senescence in different systems (15, 17, 46).”
Backgroundp53 downregulates the Fanconi anaemia DNA repair pathway
Jaber, S., Toufektchan, E., Lejour, V., Bardot, B., & Toledo, F. (2016) · Nature Communications · doi:10.1038/ncomms11091 · Cited by 61
“Defects in DNA repair activate p53 (1), and activated p53 downregulates several FA genes (2), which would attenuate the FA pathway and cause partial defects in DNA repair (3), hence defining a positive-feedback loop (in green).”
BackgroundSelf-citation
Metadata
- Authors
- Simeonova, I., Jaber, S., Draskovic, I., Bardot, B., Fang, M., Bouarich-Bourimi, R., Lejour, V., Charbonnier, L., Soudais, C., Bourdon, J.-C., Huerre, M., Londono-Vallejo, A., & Toledo, F.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 3
- Issue
- 6
- Pages
- 2046-2058
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2025225582
- Cited by
- 83
- References
- 21
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.